CPC A61K 38/465 (2013.01) [A01N 63/00 (2013.01); A61K 31/7105 (2013.01); A61K 31/713 (2013.01); A61K 45/06 (2013.01); C12N 9/16 (2013.01); C12N 9/22 (2013.01); C12N 15/113 (2013.01); C12N 15/74 (2013.01); C12Y 301/00 (2013.01); C12N 2310/10 (2013.01); C12N 2310/20 (2017.05); C12N 2795/10331 (2013.01); C12N 2795/10332 (2013.01); C12N 2795/10343 (2013.01); C12N 2795/10371 (2013.01)] | 12 Claims |
1. A method comprising:
exposing a microbiota in a human patient to an antimicrobial agent to selectively kill cells of a first bacterial species in the microbiota,
wherein selectively killing the cells of the first bacterial species is carried out by cutting a target site comprised by the genomes of the first bacterial species,
wherein the cutting is carried out using a Cas nuclease of a Type I, Type II, or Type III CRISPR system that cleaves the target site; and
wherein the selective killing is carried out by avoiding killing second cells comprised by the microbiota, wherein the second cells are of a different strain or a different species from the cells of the first bacterial species.
|